There is no routine screening test for uterine cancer recommended for women at average risk. Unlike cervical cancer, which has the Pap smear, or breast cancer, which has the mammogram, uterine (endometrial) cancer relies primarily on symptom awareness rather than scheduled screening. For women at high risk due to genetic conditions, specific screening protocols do exist starting as early as age 30.
The American Cancer Society’s position is straightforward: all women reaching menopause should be informed about the risks and symptoms of endometrial cancer and strongly encouraged to report any unexpected bleeding or spotting. There is no evidence supporting routine screening of women without symptoms, and some evidence that screening asymptomatic women causes more harm than benefit through false positives and unnecessary procedures.
Why Routine Screening Isn’t Recommended
Uterine cancer differs from many other cancers in one important way: it almost always announces itself early. The most common first sign is abnormal vaginal bleeding, particularly any bleeding after menopause. Because this symptom tends to appear while the cancer is still in its earliest, most treatable stage, a screening program for women without symptoms wouldn’t catch many additional cases that wouldn’t already be caught by paying attention to bleeding patterns.
That said, “no routine screening” doesn’t mean “no detection tools.” It means the approach is symptom-triggered. When something abnormal shows up, your doctor has several reliable ways to investigate.
What Postmenopausal Bleeding Actually Means
Any bleeding after menopause deserves medical attention, but it helps to know the odds. A large meta-analysis found that only about 9% of women with postmenopausal bleeding are ultimately diagnosed with endometrial cancer. The number varies somewhat by region and whether you use hormone therapy, ranging from about 5% to 13%, but the takeaway is clear: postmenopausal bleeding is usually caused by something benign. Thinning of the vaginal or uterine lining, polyps, and hormonal fluctuations are far more common explanations.
Still, 9% is not a number to ignore. That’s roughly 1 in 11 women with this symptom. The evaluation process is fast and well-established, and early-stage uterine cancer has excellent treatment outcomes. Reporting the symptom promptly is the single most effective “screening” strategy for the general population.
Transvaginal Ultrasound
When you report abnormal bleeding, one of the first steps is often a transvaginal ultrasound. A small probe is inserted into the vagina to create images of the uterus, allowing your doctor to measure the thickness of the uterine lining (endometrium). In postmenopausal women with bleeding, a lining thickness of 5 millimeters or more is generally considered the threshold that warrants further investigation with a biopsy. Below that cutoff, cancer is unlikely.
It’s worth noting that this 5 mm threshold applies specifically to postmenopausal women who are bleeding. For postmenopausal women without bleeding, there’s no established consensus on what endometrial thickness is considered normal versus concerning, which is another reason routine ultrasound screening isn’t recommended.
Endometrial Biopsy: The Primary Diagnostic Tool
The endometrial biopsy is the most direct way to check for uterine cancer. A thin, flexible suction tube is passed through the cervix into the uterus to collect a small sample of the lining, which is then examined under a microscope. The whole procedure takes between 5 and 15 minutes and is done in a doctor’s office, not a hospital.
The setup feels similar to a Pap smear. You lie back on an exam table with your feet in stirrups, and your doctor inserts a speculum to see the cervix. After cleaning the cervix with a solution, they may use a small instrument called a tenaculum to hold it steady. Many women find this step the most uncomfortable part. The suction tube is then inserted, and your doctor moves it around briefly to gather the tissue sample.
Expect mild to moderate cramping similar to menstrual cramps during and after the procedure. Some people find it mildly painful, though the discomfort is brief. The most commonly used device, called a Pipelle, has strong diagnostic accuracy for detecting cancer: studies report a sensitivity of about 89% and a specificity of 100%. That means it catches most cancers and almost never flags something as cancer when it isn’t. The roughly 11% it misses are typically cases where the biopsy didn’t sample the exact area of the abnormality.
When a Hysteroscopy Is Needed
If an endometrial biopsy comes back inconclusive, doesn’t collect enough tissue, or if your doctor suspects a focal lesion like a polyp, the next step is often a hysteroscopy. This involves inserting a thin, lighted camera through the cervix into the uterus so the doctor can directly see the uterine lining and take targeted biopsies from specific areas that look abnormal.
The key advantage over a standard biopsy is precision. A regular biopsy samples blindly, which means it can miss small or localized abnormalities. Hysteroscopy combined with biopsy is more accurate for distinguishing between polyps, precancerous changes, and cancer, particularly for focal lesions. For polyps larger than one-third of the uterine cavity, especially in women over 60 or those with postmenopausal bleeding, removal of the entire polyp is generally recommended so the whole specimen can be analyzed.
Screening for High-Risk Women
The one group that does benefit from proactive screening is women with Lynch syndrome, a hereditary condition that significantly increases the risk of several cancers, including endometrial cancer. Women with Lynch syndrome have a lifetime risk of uterine cancer that can reach 40% to 60%, compared to about 3% in the general population.
For these women, screening typically begins between ages 30 and 35. The protocol involves an endometrial biopsy every one to two years. Some specialists also add regular transvaginal ultrasounds to monitor changes in the uterus over time. If you know you carry a Lynch syndrome mutation, or if your family has a strong pattern of colon, uterine, or ovarian cancers, genetic counseling can help determine whether this screening schedule applies to you.
Blood Tests and Their Limitations
You may have heard of the CA-125 blood test, which is sometimes used in gynecologic cancers. While CA-125 levels can be elevated in endometrial cancer, this test is not useful for screening. CA-125 is a protein that can be elevated by many conditions, including endometriosis, fibroids, liver disease, and even pregnancy. Its value lies mainly in monitoring women who have already been diagnosed, particularly tracking whether cancer has recurred after treatment. Even in that role, routine CA-125 monitoring for endometrial cancer patients is not currently endorsed by major gynecologic oncology organizations due to limited evidence of benefit.
Symptoms That Should Prompt Evaluation
Since symptom awareness is effectively the screening strategy for uterine cancer, knowing what to watch for matters. The most important warning signs include:
- Any vaginal bleeding after menopause, even light spotting
- Unusually heavy or prolonged periods in premenopausal women, especially after age 40
- Bleeding between periods
- Pelvic pain or pressure that doesn’t resolve
- Watery or blood-tinged vaginal discharge
Women with additional risk factors, including obesity, diabetes, a history of taking estrogen without progesterone, or a family history of Lynch syndrome, should be especially attentive to these symptoms. The majority of uterine cancers are diagnosed at an early stage precisely because bleeding prompts a timely visit, and early-stage disease has a five-year survival rate above 90%.